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1. Introduction 
Metabolism generates energy for organisms to sustain all kinds of biological functions, such 
as cell growth and cell apoptosis. The immune system requires an adequate energy supply 
for its optimal function [1]. During the activation and differentiation of T cells, the balance 
between glycolysis and lipid oxidation shifts in order to cater for the cell’s energy 
requirements [2]. There is increasing evidence that shows how metabolism has an important 
role in regulating immunity, and a series of molecules have been described to play a 
functional role in both metabolism and the regulation of immune responses [3; 4; 5]. 
Uncovering the transcriptional regulation of the proteins participating in these metabolic 
processes allows us to understand how metabolism regulates T cell fate [6]. A set of non-
coding RNAs called microRNA (miRNA), can also regulate these metabolic networks by 
binding to the 3’UTR of its target transcripts [7; 8; 9].  
Autoimmune diseases were thought to be primarily caused by the immune response 
towards self-antigens. Organ-specific autoimmune diseases, such as multiple sclerosis, 
thyroiditis and type I diabetes, tend to arise due to T cell-mediated damage [10]. Abnormal 
metabolic changes may thus alter T cell function leading to the development of human 
diseases, including autoimmune diseases [11]. 
In this chapter, we highlight the recent research advances in metabolism, in particular to: 
1. The role of metabolism in T cell differentiation and function. 
2. The role of miRNAs in metabolic processes. 
3. Dysregulation of metabolism during autoimmunity. 
2. The role of metabolism in T cell differentiation and function 
The role of cellular metabolism is to generate energy and supply biosynthetic demands in 
order to sustain normal biological functions. In the immune system, the control of cell 
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numbers and activity of different T cell subsets is important for generating an appropriate 
immune response to combat foreign pathogens and prevent the risk of developing 
autoimmunity. The fate of T cells is strongly linked to metabolism by regulating cell growth, 
survival, function and differentiation. 
Naive T cells, having undergone positive and negative selection in the thymus [12; 13], enter 
the periphery and encounter their specific cognate antigens in the context of major 
histocompatibility complexes to become activated, and differentiate into effector T (Teff) or 
induced regulatory T (Treg) cells. Metabolically, naive T cells consume glucose and other 
essential nutrients at a low rate, enough to supply energy to maintain normal housekeeping 
functions [14]. Importantly, naive T cells require extrinsic signals to maintain sufficient 
levels of glucose metabolism to prevent atrophy and apoptosis [15]. 
T cells are activated through the T cell receptor (TCR) and CD28 by the engagement of 
MHC-peptide complexes and B7 family members on antigen presenting cells. During this 
process, the physiological and phenotypic repertoire of the T cells develop in a way to 
support rapid cell growth, proliferation, and the generation of effector T cells, in which 
metabolism plays a critical role [16]. To drive enhanced glucose metabolism in activated T 
cells, the upregulation of expression and trafficking of glucose transporter 1 (Glut1) is 
crucial [17] (Fig. 1). The downregulation of Glut1 in lymphoid cell lines can decrease 
proliferation and cause cell cycle arrest or apoptosis [18; 19]. In contrast, the transgenic 
overexpression of Glut1 in T cells increases cell size, cytokine production, and proliferation 
upon activation [20]. 
The expression of Glut1 in T cells is induced by activation with a strong TCR agonist or 
through the cross-linking of the TCR-associated CD3 protein [21]. Both the MAPK pathway 
(p38) and Myc activation are upstream of Glut1 activation [22; 23] and may mediate the TCR 
dependent control of Glut1. TCR signaling can also activate AMP-activated protein kinase 
(AMPK) [24], which upregulates glucose uptake to promote energy generation [25] and may 
be due in part to the upregulation of Glut1 expression. Following the loss of the TCR, naive 
T cells downregulate the expression of Glut1 [26]. Mitochondrial potential and cellular ATP 
levels are also reduced, which suggests the loss of glucose metabolism. Beside the TCR, 
interleukin (IL)-7 is also a key regulator of glucose uptake in T lymphocytes. IL-7 maintains 
glucose metabolism by promoting Glut1 trafficking [27]. The tyrosine residue at position 449 
of IL-7Rα is required for IL-7–mediated regulation of glucose uptake, which promotes rapid 
activation of signal transducer and activator of transcription 5 (STAT5) and a delayed yet 
sustained activation of Akt [28].  
The intracellular trafficking of Glut1 is important for its localization to the cell surface to 
support glucose uptake. Co-stimulation through CD28 ligation can provide a strong signal to 
direct the trafficking of Glut1 to the cell surface through the activation of the 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway [29]. Akt can be activated through 
the ligation of its N-terminal pleckstrin homology (PH) to phosphatidylinositol (3,4,5)-
triphosphate (PIP3) at the plasma membrane, generated by PI3K from PIP2, and its subsequent 
phosphorylation by 3'-phosphoinositide-dependent protein kinase-1 (PDK-1) [30]. Once 
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activated, Akt can interact with and modulate the activity of different binding partners. The 
increased glucose uptake and augmented glycolysis observed upon CD28 co-stimulation can 
be prevented by LY294002-mediated PI3K inhibition [29], which induces a significant down-
modulation of Glut1. Conversely, PI3K activation is inhibited by cytotoxic T lymphocyte 
antigen-4 (CTLA-4), results in Glut1 internalization where it is targeted to lysosomes for 
degradation and prevents the upregulation of glucose metabolism in activated T cells [31]. 
Although Glut1 plays a central role in T cell glucose metabolism, there are still other 
regulators downstream of the initial glucose uptake. For example, Akt increases hexokinase 
activity to increase glucose phosphorylation to prevent its transport out of the cell [32; 33]. 
In addition, Akt can also promote the activity of the key glycolytic enzyme, 
phosphofructokinase, by the phosphorylation of phosphofructokinase-2 and generation of 
the allosteric activator, 2,6-phospho-fructose [34]. Myc, better known as a regulator of 
proliferation and apoptosis [35], has also been shown to play a pivotal role in activation-
induced glycolysis, being necessary for the upregulation of glycolytic enzymes and 
transporters. However, it still remains unclear as to how these pathways are integrated into 
T cell metabolism. 
T cell activation induces a rapid elevation in oxygen consumption [36]; however, the 
most dramatic increase is in glycolysis. This results in the significant increase in the 
production of lactate, which can adequately guarantee an efficient but quick energy 
supply to the cell [1; 2; 37]. This glycolytic program supplies energy to T cells during 
their rapid differentiation, and the increase in intracellular glucose levels supports the 
pentose phosphate pathway required for the synthesis of nucleic acids, NADPH for 
producing ATP, and lipid synthesis [38]. This metabolism shift to high glycolysis can 
influence T cell function and survival. When glucose metabolism is limited in activated T 
cells, there is a decrease in the proliferation and production of interferon-γ (IFN-γ),  
and an increase in the expression and activation of pro-apoptotic Bcl-2 family proteins 
[39; 40].  
Naive T cells can differentiate into different T cell subsets after stimulation, and during 
differentiation the metabolic program must match the demands of each cell function. 
Treg cells and T helper cells have different metabolic phenotypes: Treg cells prefer lipid 
oxidation and helper T (Th) cells prefer the glycolytic program. Different metabolic 
culture conditions can thus influence T cell differentiation in vitro [2]. The inhibition of 
mTOR and activation of AMPK can increase and decrease the percentage of Treg and Th 
cells, respectively [2]. Hypoxia-inducible factor 1α (HIF1α) is required for the 
upregulation of glycolytic activity, the promotion of Th17 differentiation and inhibition 
of Treg cell differentiation. HIF1α is a key metabolic factor in the mTOR-dependent 
upregulation of glycolysis observed under Th17-skewing conditions [5] and negatively 
regulates Forkhead Box P3 (FOXP3) to inhibit Treg cell differentiation [41]. 
Leptin, a 16-kDa non-glycosylated protein encoded by the ob gene, is classically 
considered a hormone, as it regulates the balance between food intake and energy 
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expenditure. The level of serum leptin is levels is correlated directly with body-fat stores, 
increasing with fat accumulation and decreasing during fasting [4]. In recent years, 
leptin has been proved to be an immune response regulator. Mice with a genetic 
deficiency of leptin (ob/ob) or leptin receptor (ObR) have a reduced susceptibility to 
autoimmunity [42; 43]. Leptin has a specific effect on T cell responses partly by 
increasing Th1 and suppressing Th2 cytokine production. Also, leptin antibody can 
enhance the proliferation and suppress the function of Treg cells by down modulating 
the cyclin dependent kinase inhibitor p27 (p27kip1), and the phosphorylation of the 
extracellular-related kinases 1 (ERK1) and ERK2 [44]. 
There is still much unknown regarding the complete mechanisms of metabolism in T cell 
function in a physiological setting. These mechanisms could also be tissue specific, and the 





Figure 1. Glucose metabolism is activated by TCR, CD28 and cytokines in T cells.  The increase in 
glycolysis is dramatic during T cell activation. In this process, the expression and intracellular 
trafficking of glucose transporter 1 (Glut1) is important as Glut1 controls the first step of glycolysis by 
facilitating the transport of glucose across the plasma membrane. The expression of Glut1 is 
upregulated by TCR and CD28 activation, while the trafficking to the cell surface is potentiated by 
signals from TCR, CD28 and IL-7 via Akt.  
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3. The role of miRNAs in metabolic processes 
Metabolism interferes with the fate of T cells and plays a crucial role in the regulation of 
immunity. Cytokine/TCR signals and many growth factors have been reported to regulate 
metabolic processes [28; 29]. Moreover, microRNAs, a group of short non-coding RNA 
molecules that control gene expression by binding to the 3’ untranslated region (UTR) of 
complementary target mRNAs, are also involved in the regulation of metabolic networks 
[45; 46]. Here, we summarize the recent findings of metabolism regulating miRNAs and 
whether they currently play a role in T cell perturbation either directly or indirectly. 
Insulin-related cell signal pathways regulate glucose metabolism and are related to the 
development of diabetes. The first miRNA identified in this program is the evolutionarily 
conserved and islet-specific miRNA, miR-375, which regulates glucose-induced insulin 
secretion by inhibiting the expression of Myotrophin (Mtpn) [47]. Further studies have 
indicated that miR-375 is regulated by glucose and that miR-375 inhibits glucose-induced 
INS-1E cell proliferation via the targeting of PDK-1 [48]. miR-375 has also been found to 
affect palmitate-induced lipoapoptosis in NIT-1 cells, a NOD-derived β-cell line [49]; here, 
mir-375 increases the susceptibility to palmitate-induced lipoapoptosis by targeting Mtpn. 
Thus, miR-375 emerges as a novel pharmacological target for the treatment of diabetes. 
Additionally, it has been shown that miR-375 can regulate the expression of thymic 
stromal lymphopoietin, a Th2-skewing cytokine in epithelia to help control parasitic 
infection [50]. 
miR-9 is another miRNA that has a possible role in insulin secretion by targeting Onecut-2 
(OC-2) [51]. As OC-2 is a negative regulator of granuphilin, which is known as a key 
regulator of insulin secretion by repressing insulin exocytosis [52], miR-9 is proposed to 
negatively regulate insulin exocytosis. Furthermore, miR-9 expression is regulated during 
glucose-stimulated insulin secretion and modulates Sirtuin 1 (Sirt1) expression in vivo [53], a 
deacetylase that has been implicated in stabilizing Treg cells by stabilizing the expression of 
its master transcription factor FOXP3 [54]. 
The Lin-28/let-7 axis is also involved in glucose metabolism. Overexpression of Lin28a/B in 
mice results in insulin sensitivity, enhanced glucose tolerance, and resistance to diabetes, 
while overexpression of let-7 has the opposite effect [7]. The insulin-PI3K-mTOR signalling 
pathway, which regulates growth and glucose metabolism can be activated by Lin28a/B and 
suppressed by let-7. let-7 target genes in human are associated with type 2 diabetes, and it is 
suggested that enhancing Lin28 or abrogating let-7 may be therapeutically promising for 
treating diseases such as obesity and diabetes. Although the role of this axis has not been 
extensively investigated in T cells, it has been shown that let-7 is involved in regulating the 
sensitivity of T cells to Fas-mediated apoptosis [55]. The mTOR signalling pathway has also 
been shown to be regulated by miR-199a-3p, which alters the susceptibility of tumour cells 
to hypoxia [56]. 
In cardiomyocytes, miR-133 reduces insulin-mediated glucose uptake by decreasing GLUT4 
expression. miR-133 is believed to be expressed specifically in adult cardiac and skeletal 
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muscle tissues where it regulates the differentiation and proliferation of these cells [57]. It 
has been confirmed that the overexpression of miR-133 reduces the protein level of Kruppel-
like factor 15 (KLF15) followed by its downstream target GLUT4. Silencing endogenous 
miR-133 in vitro increases the levels of KLF15 and GLUT4, which indicates a role of miR-133 
in the metabolism of cardiac myocytes [8]. Insulin signalling can be regulated by miR-33a/b, 
which targets the insulin receptor substrate 2, an essential component of the insulin-
signalling pathway in the liver [58]. miR-33a/b also regulates fatty acid metabolism by 
targeting several key enzymes involved in the regulation of fatty acid oxidation, including 
carnitine O-octaniltransferase, carnitine palmitoyltransferase 1A, hydroxyacyl-
CoAdehydrogenase, Sirt6, and AMP kinase subunit-α [58]. Thus, mir-33a/b acts as a 
negative regulator of both insulin signalling and fatty acid oxidation in hepatic cell lines. 
There has yet to be any findings regarding the role of miR-133 and miR-33a/b in the 
modulation of T cells. 
The liver specific miRNA, miR-122, is a key regulator of cholesterol and fatty-acid 
metabolism. Inhibition of miR-122 in the mouse liver results in reduced plasma cholesterol 
levels, increased hepatic fatty-acid oxidation, a decrease in hepatic fatty-acid and cholesterol 
synthesis rates, and the activation of AMPK [59]; interestingly, miR-122 can be induced by 
miR-370, which in turn induces lipogenic genes leading to the regulation of Cpt1α [60]. 
Although primarily thought to be expressed in the liver, miR-122 has been shown to be 
expressed in lymphoma cells. Its upregulation protects these cells towards chemotherapy-
induced cytotoxicity [61]. AMPK is also regulated by miR-451. In glioma cells it has been 
found that increased glucose levels upregulates miR-451 which in turn regulates the AMPK 
pathway to promote cell growth [62].  
HIF1, shown to promote Th17 but inhibit Treg cell differentiation [41], has been found to 
upregulate miR-210 in hypoxic cells. This increase is proposed to provide tumour cells the 
ability to survive under stressful conditions [63; 64]. The negative regulation of HIF1 itself 
has been found through the miR-17-92 cluster [65], miR-22 [66], miR-20b [67; 68], and 
miR-519c [69], and positively regulated indirectly through miR-31 [70] by the 
downregulation of factor-inhibiting hypoxia inducible factor and miR-130 through the P-
body protein DDX6 [71]. In turn, miR-31 and miR-210 negatively regulates FOXP3 
expression in Treg cells [72; 73], which would correlate with their roles in positively 
regulating HIF1 responses and Th17, but not Treg differentiation. Interestingly, HIF1α can 
also be negatively regulated by miR-155 [74], a miRNA that is highly upregulated in Treg 
cells induced by FOXP3 [75]. Also, miR-199a targets both HIF-1α and Sirt1, and thus may 
play a role in Treg cell differentiation [76; 77]. The miR-17-92 cluster also promotes Th1 
responses and prevents induced Treg cell differentiation [78]. Finally miR-130, has also 
been found to be upregulated upon TCR stimulation of CD8+ T cells, and downregulates 
CD69 during differentiation [79]. Even with the wealth of information above, there is a 
lack of evidence that these miRNAs regulate HIF1 in T cells to contribute to the control of 
the differentiation of various T cell subsets. 
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Recent studies have demonstrated that miRNAs are pivotal in T cell development and 
function [80; 81; 82], which indicates that miRNAs are one of the important regulators of the 
immune system. miRNAs have also been implicated in regulating metabolic pathways, 
mostly identified thus far in non-immune cells in controlling blood glucose levels (Fig. 2). 
More research is required to identify whether miRNAs are also involved in the metabolic 
regulation of T cells. The identification of miRNA signatures in various T cell subtypes may 
provide clues towards the cross-regulation between metabolism and miRNA networks in 
lymphocytes [83].  
 
Figure 2. The regulatory network of microRNAs in pancreatic β-Cells. In pancreatic β-Cells some 
miRNAs participate in the insulin signal pathway. miR-375, which is downregulated by glucose, 
suppresses glucose-induced insulin secretion by inhibiting the expression of Myotrophin (Mtpn) and 
inhibits glucose-induced cell proliferation by targeting PDK-1. Glucose can enhance the expression of 
miR-9-2 and miR-9-3, which target Sirt1.  
4. Dysregulation of metabolism during autoimmunity 
The metabolic status of immune cells determines their fate and role in the immune system. 
The basic bioenergetic demands of resting lymphocytes can be essentially supplied by 
oxidative phosphorylation [84], while the increased amount of energy required during their 
activation implies a shift towards aerobic glycolysis. Much evidence exists regarding the 
role of Akt in the activation of mTOR, involved in a myriad of cellular processes, including 
translation, transcription, autophagy, growth and proliferation. mTOR is also known as a 
nutrient and energy “sensor”, since it regulates the expression of multiple nutrient 
transporters [85]. Several studies have indicated that the Akt and mTOR pathways are 
intimately connected, given that the latter can be modulated by Akt, which in turn seems to 
be sensitive to mTOR inhibition by rapamycin [86; 87]. 
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Autoimmune diseases comprises a large number of pathologies characterized by 
exacerbated immune responses against self-antigens. The mechanisms leading to 
autoimmunity are not yet fully understood, but their multifactorial basis is almost clear. 
Given the involvement of these pathways in the activation and differentiation of multiple T 
cell subsets, it is conceivable that alterations in the expression and/or function of one or 
more of the factors involved can lead to a breakdown in immune homeostasis. 
Indeed, both systemic and organ-specific autoimmune diseases seem to rely on genetic, 
infectious and environmental predisposing factors [88]. Systemic lupus erythematosus (SLE) 
is the prototype of systemic autoimmune diseases. Subjects affected are characterized by a 
strong hyperactivation of autoreactive CD4+ T cells and a consequent aberrant expansion of 
B lymphocytes. Large amounts of autoantibodies are secreted, mostly targeting nuclear 
antigens and affecting skin, joints, blood vessels and the central nervous system (CNS) [89]. 
Glomerulonephritis can also occur, due to deposition of immunocomplexes in the kidney. 
Several studies have found in SLE patients marked deficiencies in the number and/or 
suppressive capacity of CD4+CD25high Treg cells [90; 91], although early works also 
identified the abnormal resistance to suppression of Teff cells as a major issue in the loss of 
tolerance characterizing SLE [92]. 
From a molecular point of view, current hypotheses support a sustained activation of the 
Akt-mTOR axis in SLE. In a well known model of murine lupus, the New Zealand Black 
White (NZBW)/F1 hybrid has an elevated expression and activation of Akt and mTOR at the 
glomerular level. Treatment of mice with rapamycin inhibits Akt and mTOR activation, thus 
prolonging mice survival and ameliorating the clinical course of the disease [93]. The hyper-
activation of the Akt pathway in CD4+ T cells from MRL/lpr mice, a model of spontaneous 
lupus, could also be inhibited by the use of specific PI3Kγ inhibitors [94]. An increase in Akt 
activation has been demonstrated in the peripheral blood from SLE patients, concurrently 
with an up-regulation of the phosphorylation of one of its downstream targets, GSK3β [95], 
known as a negative regulator of cell cycle progression [96]. An abnormal activation of 
mTOR has been demonstrated in human SLE [97], and promising results in the treatment of 
the disease have been obtained with rapamycin, which could act by facilitating the 
differentiation of Treg cells and promoting the expansion of other subsets able to limit the T 
cell stimulation of auto-reactive B cells [98]. Beyond Akt and mTOR, a dysregulation in 
leptin expression has also been found in SLE patients [99; 100], but further studies are 
required to unlock the mechanisms that control its secretion. 
A role for the Akt-mTOR axis has also been demonstrated in the pathogenesis of multiple 
sclerosis (MS). MS is an inflammatory disease of the central nervous system, characterized 
by the presence of CD4+ autoreactive T cells able to target myelin-based antigens, thus 
causing the progressive formation of demyelinating lesions and neuronal degeneration 
[101]. Given the target of inflammation, MS is considered an organ-specific autoimmune 
disease. Several studies have tried to clarify the role of different T cell subsets in MS, but 
the complex network of immune cells in this pathology does not make this an easy task. 
In particular, the role of the Treg subsets has not yet been clearly addressed. No 
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differences in numbers of Treg cells seem to exist between healthy subjects and MS 
patients, at least in the peripheral blood, and an increased number has been observed in 
the cerebrospinal fluid [102]. However, alterations in the Treg pool and function have 
been found [102; 103; 104]. Interestingly, gene-expression profile analysis of brains from 
post-mortem MS patients revealed a strong up-regulation of genes involved in cellular 
metabolism, such as Akt and HIF1α [105]. This is consistent with the findings that T cells 
from HIFα-/- mice restimulated ex vivo with myelin oligodendrocyte glycoprotein (MOG) 
peptide display a reduced secretion of IL-17 and are poorly efficient to induce 
experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice [52]. Moreover, 
rapamycin administration is efficacious in treating EAE due to its dual action both on 
Treg and Teff cells [106]. The Akt-mTOR pathway seems to be subjected to leptin 
regulation during the development of EAE. Indeed, MOG-specific CD4+ T cells from 
leptin deficient (ob/ob) mice display a reduction in the activation of Akt and S6, 
downstream of mTOR. Ob/ob mice are resistant to adoptively transferred EAE [42; 107], a 
condition that can be restored by recombinant leptin administration [42]. In humans, 
increased levels of leptin has been detected in the CNS of MS patients [108].  
Inhibitors of the mTOR pathway, such as sirolimus (rapamycin), are already used for the 
treatment of some autoimmune diseases, and many of its analogs constitute as promising 
candidates for a wide range of autoimmune diseases. Further study is required to reveal the 
metabolic signature of each disease in more depth, hence allowing the development of more 
specific and efficacious treatments. 
A clear link has been established between Treg cells and type 1 diabetes (T1D), an 
inflammatory-autoimmune disease characterized by the inflammation and destruction of 
insulin-producing beta cells of the pancreas. This is particularly evident in individuals with 
IPEX (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome), in 
which the lack of Treg cells is associated with an increased susceptibility to diabetes [109]. 
The onset and progression of the pathology does not seem to be related to an altered 
number of Treg cells, since most works have demonstrated that there are no differences 
between T1D subjects and healthy controls in the peripheral blood [110; 111]. Most likely, a 
decreased suppressive capacity of Treg cells and an enhanced resistance to suppression of 
Teff cells seem to be the basis of the loss of self-tolerance observed in T1D [112; 113]. What 
really is hidden behind the alterations in T cell functions is still a matter of debate, but 
results from an early study have pointed out a strong activation of Akt in splenocytes from 
NOD mice, which could be prevented by the use of the PI3Kγ inhibitor AS605240 [114]. The 
amelioration observed in the clinical signs of diabetes after PI3K inhibition could be a 
consequence of the increase in Treg expansion as well as Teff suppression, probably due to 
the activation of cAMP response element-binding protein (CREB), a transcription factor 
shown to be involved in Foxp3 expression [115]. Anomalies in the number and function of T 
cell subsets have been also proved in other autoimmune diseases, such as rheumatoid 
arthritis (RA) [116] and psoriasis [117], but we are still far from clarifying the underlying 
molecular mechanisms behind their progression (Fig. 3).  
Autoimmune Diseases –  
Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies 86 
 
Figure 3. The metabolic factors influencing the immune system and autoimmune diseases. The balance 
between Treg and Teff function is crucial toward the maintenance of self tolerance. Akt, mTOR, HIF1α, 
Myc and Leptin are involved in tipping this balance, and the result of the dampening of Treg function 
or augmentation of Teff function could lead to the development of SLE, MS, T1D or RA. 
Several studies have tried to highlight the genetic and metabolic background that predisposes 
individuals to autoimmune diseases preceding their onset, but this has been difficult due to 
the complex network of the different factors involved. A clear risk factor for the development 
of autoimmunity is represented by the presence of polymorphisms in the Human Leukocyte 
Antigen (HLA) class II locus, but non-HLA loci have also recently been identified. Some 
“autoimmune loci”, such as IL2RA, CTLA4, IL23R, IL10 and PTPN22 are shared by a wide 
range of diseases, while others seem to be specific, such as the VTCN1 (V-set domain 
containing T cell activation inhibitor 1) locus for SLE [118]. Allelic variants in the PTPN22 
locus, encoding for Lymphoid protein tyrosine phosphatase (Lyp), have been associated with a 
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high predisposition to autoimmune diseases, including T1D, MS, SLE and RA. Protein tyrosine 
phosphatases (PTPs) catalyse the release of phosphate groups from tyrosine residues on 
signalling intermediates, thus playing a fundamental role in activating/deactivating specific 
transduction pathways. PTPs have been demonstrated to modulate the signalling events 
following T cell receptor (TCR) engagement with MHC-peptide complexes that lead to the 
activation and differentiation of T cells [119]. From a metabolic point of view, follow-up 
studies indicate that specific “lipidomic” profiles, such as low triglycerides, low levels of 
lysophosphatidylcholine and multiple phospholipids characterize the sera of children that 
later progress to T1D, as well as anomalies in the levels of glutamine, α-ketoglutarate and 
other amino acids [120; 121; 122; 123]. The adoption of metabolomics at a high-throughput 
level has also been useful to uncover these patterns [124]. Vitamin D deficiency has been 
associated with the increased likelihood of the development of autoimmune disease [125], 
including type 1 diabetes, and has been linked to key genes involved in the metabolism of 
25(OH)D [126]. Despite the lack of direct evidence regarding the behaviour of different T cells 
subsets prior to the onset onset of autoimmune diseases, specific alterations in the levels of 
these modulators can be used to assess an individual's predisposing susceptibility to 
autoimmunity. Analysing specific T cell markers on a large scale and integrating them with 
certain genetic and metabolic biomarkers could become a powerful tool for predicting the risk 
and prognosis of specific autoimmune diseases. 
5. Conclusion 
Metabolism has an undoubtedly important role in the definition of the T cell repertoire. The 
constituents of the microenvironment or modulation of T cell responsiveness towards the 
environment controls the direction in which T cells differentiate. This, in turn, could lead to the 
development of autoimmune disease if the proinflammatory players prevail against opposing 
antiinflammatory cues. Although it is becoming clearer as to the role of metabolic networks in 
defining T cell fate and the development of autoimmunity—the molecular basis, especially the 
role of miRNAs in controlling T cell metabolism and sensitivity towards extracellular metabolic 
factors, remain unclear. Various drugs have been produced to tackle tumour growth from a 
metabolic point of view, and new strategies are emerging to target miRNAs as a therapy. Thus, 
the lessons learned from these fields may also contribute towards future therapeutic solutions 
against autoimmunity by specifically targeting T cells at the heart of metabolism. 
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